Histotripsy treatment for small liver tumours in Asia
Official title: Histotripsy Ablation for Liver Tumours (HALT): A Multi-centre Prospective Pilot Study on the Safety and Efficacy of Histotripsy in Asian Primary and Secondary Liver Malignancies
Run by National Cancer Centre, Singapore · NCT07428356 · Data updated 2026-11-12
This trial will try using histotripsy, a noninvasive focused-ultrasound treatment, to destroy small liver tumors in adults in Asia who are not candidates for surgery or other local therapies.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years to 99 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | National Cancer Centre, Singapore Academic / other |
| Locations | 3 sites (Singapore and 2 other locations) |
| Status | Recruiting |
| Started | November 7, 2025 |
| Main results expected | November 7, 2027 |
| Study ends | May 7, 2029 |
| Registry record updated | October 8, 2026 |
| Trial ID | NCT07428356 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥21 years) with up to three ultrasound-visible liver lesions each ≤3 cm, ECOG 0–1, Child–Pugh A or B7 if cirrhotic, adequate organ function, and who are not eligible for or have declined surgery or other locoregional treatments or have oligoprogressive disease on systemic therapy.
✕Probably not a fit
Patients with more than three lesions, lesions larger than 3 cm, lesions not visible/targetable by ultrasound, poor performance status, or diffuse/uncontrolled liver disease are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-arm, multi-centre prospective pilot trial in Singapore using the HistoSonics Edison system to ablate up to three liver lesions per patient (each ≤3 cm) under general anaesthesia. It enrolls adults with primary or secondary liver-limited malignancies or patients with oligoprogressive liver disease while on systemic therapy. Patients will have baseline imaging and labs, undergo histotripsy, and be followed at predefined intervals for clinical, radiologic, and biomarker outcomes. Translational endpoints include immune profiling of PBMCs and cytokines, microbiome analysis, and optional tumor biopsies to characterize biological effects and tolerability in an Asian population.
Why it matters
Potential benefit: If successful, histotripsy could offer a noninvasive way to destroy small liver tumors while preserving healthy liver tissue and potentially enhancing anti-tumor immune responses.
How similar studies have gone: Early preclinical and small clinical studies of histotripsy have shown promising feasibility and local tumor control with immune effects, but large-scale evidence is limited and its use specifically in Asian liver cancer populations is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥21 years at the time of consent. 2. Histologically/cytologically confirmed cancers (imaging diagnosis as per AASLD allowed for HCC): A) Liver limited malignancies (primary or secondary) not eligible for/declined resection or other locoregional treatment modalities. B) All solid cancer patients (e.g., HCC, colorectal, breast, pancreatic cancers etc) undergoing systemic therapy with oligoprogressive liver disease (defined as ≤ 3 liver limited progressive lesions, ≤ 3 cm in maximum diameter having received \> 3 months of systemic therapy). 3. Characteristics of hepatic lesions intended for treatment: * Up to 3 hepatic lesions. * Tumour ≤ 3 cm in longest diameter. * Lesion(s) must be visible and targetable by ultrasound. 4. ECOG Performance Status 0-1. 5. Child-Pugh class A or B7 liver function for patients with underlying cirrhosis. 6. Adequate hematologic and organ function within 14 days prior to treatment: * Haemoglobin ≥ 9.0 g/dL * Platelets ≥ 75,000/mm³ * INR ≤ 1.5 × ULN * Estimated (by Cockroft-Gault or Modification of Diet in Renal Disease (MDRD) or measured creatinine clearance ≥ 50ml/min. * Total bilirubin ≤ 1.5 × upper limit normal or direct bilirubin ≤ ULN for participants with total bilirubin \> 1.5 × ULN (participants with known history of elevated indirect bilirubin level suggestive of extrahepatic source of elevation e.g. Gilbert's disease may be recruited with bilirubin levels ≤ 3 × ULN) * AST and ALT ≤ 5 × ULN 7. Ability to undergo general anaesthesia, as confirmed by pre-anaesthetic assessment. 8. Life expectancy ≥ 3 months in the opinion of the investigator. 9. Willing and able to comply with study visits and procedures. 10. Written informed consent obtained prior to any study-related procedures. Exclusion Criteria: 1. Extrahepatic disease progression requiring immediate systemic intervention, including new brain metastases or malignant ascites. 2. Vascular invasion, defined as gross involvement or encasement of major portal vein or hepatic vein branches. 3. Tumours located adjacent (\<5 mm) to hollow viscera (e.g., stomach, colon) where histotripsy poses perforation risk. 4. Lesions poorly visualized on ultrasound or not targetable due to overlying ribs or gas. 5. Severe or uncontrolled comorbidities including: * Uncontrolled hypertension or cardiovascular disease * Active infection (requiring systemic therapy) * Severe chronic obstructive pulmonary disease or hypoxia 6. Contraindications to general anaesthesia or surgery. 7. Pregnancy or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 7 days prior to treatment. 8. Participation in another interventional trial within 4 weeks prior to enrollment, or concurrent participation in a therapeutic study. 9. Any condition that, in the investigator's judgment, may compromise the patient's safety or interfere with protocol adherence.
Where it's running
-
National University Hospital
Singapore, Singapore Recruiting -
National Cancer Centre Singapore
Singapore, Singapore Recruiting -
Singapore General Hospital
Singapore, Singapore Recruiting
Study contacts
- Principal investigator: Prof Brian Goh, MBBS, MMed, MSc, FRCSEd, FAMS — National Cancer Centre, Singapore
- Study coordinator: Prof Brian Goh, MBBS, MMed, MSc, FRCSEd, FAMS
- Email: brian.goh@singhealth.com.sg
- Phone: +65 63265440
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Microwave ablation for small liver tumors
This study tests if a new microwave treatment can safely remove small liver tumors and reduce the chances of them coming back.
-
High dose-rate brachytherapy for treating unresectable liver tumors
This study is testing a new way to treat liver tumors that can't be removed with surgery to see if it helps patients live longer and keep their tumors from growing.
-
Understanding the genetic causes of childhood liver cancer
This study is trying to find out the genetic causes of childhood liver cancer to help doctors diagnose and treat these rare cancers better.
-
Needle-based treatment for liver tumors
This study is testing a new needle treatment for liver tumors to see if it can completely destroy the tumors in adults who can't have surgery.
-
Imaging, Blood, and Tissue Samples to Guide Colon Cancer and Liver Tumor Care
This study tests whether combining imaging, blood, and tissue samples can help tailor treatment for people with colon cancer and related liver tumors.
-
Local treatment for liver metastases in colorectal cancer patients
This study tests if combining local treatment for liver tumors with regular cancer therapy can help people with colorectal cancer live longer and feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.